Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

223 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Cardiac toxicity and efficacy of trastuzumab combined with pertuzumab in patients with [corrected] human epidermal growth factor receptor 2-positive metastatic breast cancer.
Portera CC, Walshe JM, Rosing DR, Denduluri N, Berman AW, Vatas U, Velarde M, Chow CK, Steinberg SM, Nguyen D, Yang SX, Swain SM. Portera CC, et al. Among authors: walshe jm. Clin Cancer Res. 2008 May 1;14(9):2710-6. doi: 10.1158/1078-0432.CCR-07-4636. Clin Cancer Res. 2008. PMID: 18451236 Free PMC article. Clinical Trial.
Economic impact of 21-gene recurrence score testing on early-stage breast cancer in Ireland.
Smyth L, Watson G, Walsh EM, Kelly CM, Keane M, Kennedy MJ, Grogan L, Hennessy BT, O'Reilly S, Coate LE, O'Connor M, Quinn C, Verleger K, Schoeman O, O'Reilly S, Walshe JM. Smyth L, et al. Among authors: walshe jm. Breast Cancer Res Treat. 2015 Oct;153(3):573-82. doi: 10.1007/s10549-015-3555-4. Epub 2015 Sep 12. Breast Cancer Res Treat. 2015. PMID: 26364296
Impact of somatic PI3K pathway and ERBB family mutations on pathological complete response (pCR) in HER2-positive breast cancer patients who received neoadjuvant HER2-targeted therapies.
Toomey S, Eustace AJ, Fay J, Sheehan KM, Carr A, Milewska M, Madden SF, Teiserskiene A, Kay EW, O'Donovan N, Gallagher W, Grogan L, Breathnach O, Walshe J, Kelly C, Moulton B, Kennedy MJ, Gullo G, Hill AD, Power C, Duke D, Hambly N, Crown J, Hennessy BT. Toomey S, et al. Breast Cancer Res. 2017 Jul 27;19(1):87. doi: 10.1186/s13058-017-0883-9. Breast Cancer Res. 2017. PMID: 28750640 Free PMC article. Clinical Trial.
Impact of timing of trastuzumab initiation on long-term outcome of patients with early-stage HER2-positive breast cancer: the "one thousand HER2 patients" project.
Gullo G, Walsh N, Fennelly D, Bose R, Walshe J, Tryfonopoulos D, O'Mahony K, Hammond L, Silva N, McDonnell D, Ballot J, Quinn C, McDermott EW, Evoy D, Prichard R, Geraghty J, Amstrong J, Crown J. Gullo G, et al. Br J Cancer. 2018 Aug;119(3):374-380. doi: 10.1038/s41416-018-0114-x. Epub 2018 May 18. Br J Cancer. 2018. PMID: 29773838 Free PMC article.
Pilot study of bevacizumab in combination with docetaxel and cyclophosphamide as adjuvant treatment for patients with early stage HER-2 negative breast cancer, including analysis of candidate circulating markers of cardiac toxicity: ICORG 08-10 trial.
Gullo G, J Eustace A, Canonici A, M Collins D, Kennedy MJ, Grogan L, Breathhnach O, McCaffrey J, Keane M, Martin MJ, Gupta R, Leonard G, O'Connor M, Calvert PM, Donnellan P, Walshe J, McDermott E, Scott K, Hernando A, Parker I, W Murray D, C O'Farrell A, Maratha A, Dicker P, Rafferty M, Murphy V, O'Donovan N, M Gallagher W, Ky B, Tryfonopoulos D, Moulton B, T Byrne A, Crown J. Gullo G, et al. Ther Adv Med Oncol. 2019 Jul 24;11:1758835919864236. doi: 10.1177/1758835919864236. eCollection 2019. Ther Adv Med Oncol. 2019. PMID: 31384312 Free PMC article.
Real-world analysis of clinical and economic impact of 21-gene recurrence score (RS) testing in early-stage breast cancer (ESBC) in Ireland.
McSorley LM, Tharmabala M, Al Rahbi F, McSorley K, Chew S, Evoy D, Geraghty JG, Prichard RS, Rothwell J, McCartan DP, McDermott EW, Keane M, Kennedy MJ, O'Reilly S, Millen SJ, Crown JP, Smyth LM, Kelly CM, Quinn CM, Walshe JM. McSorley LM, et al. Among authors: walshe jm. Breast Cancer Res Treat. 2021 Aug;188(3):789-798. doi: 10.1007/s10549-021-06211-w. Epub 2021 Apr 9. Breast Cancer Res Treat. 2021. PMID: 33835293
The role of infiltrating lymphocytes in the neo-adjuvant treatment of women with HER2-positive breast cancer.
Eustace AJ, Madden SF, Fay J, Collins DM, Kay EW, Sheehan KM, Furney S, Moran B, Fagan A, Morris PG, Teiserskiene A, Hill AD, Grogan L, Walshe JM, Breathnach O, Power C, Duke D, Egan K, Gallagher WM, O'Donovan N, Crown J, Toomey S, Hennessy BT. Eustace AJ, et al. Among authors: walshe jm. Breast Cancer Res Treat. 2021 Jun;187(3):635-645. doi: 10.1007/s10549-021-06244-1. Epub 2021 May 13. Breast Cancer Res Treat. 2021. PMID: 33983492 Free PMC article.
223 results